Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.
BASKING RIDGE, N.J. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Daniel S. Goldberger as Chief Executive Officer, effective October 1 . Mr.
Additional information requested by FDA; Premium 2 trial progressing as planned BASKING RIDGE, N.J. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR, or the “Company”), a commercial-stage bioelectronic medicine company, today announced that the U.S.
Sequential growth reported in paid months of therapy, prescribing physicians and prescriptions dispensed Company to host conference call and webcast today, August 13 , at 4:30pm ET BASKING RIDGE, N.J. , Aug. 13, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc.
BASKING RIDGE, N.J. , Aug. 12, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the company has entered into an exclusive contract with Doctor’s Medical, LLC for distribution rights to gammaCore for patients with workers’
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter and six-months ended June 30, 2019
BASKING RIDGE, N.J. , July 15, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has filed a "universal shelf" registration statement on Form S-3 (the “Registration Statement”) with the Securities and Exchange
BASKING RIDGE, N.J. , July 10, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a global commercial-stage bioelectronic medicine company, today announced data presentations focused on non-invasive vagus nerve stimulation (nVNS) to be presented at the American Headache Society’s 61 st
The National Institute for Health and Care Excellence (NICE) draft guidance recommends the use of gammaCore for cluster headache in the National Health Service (NHS) LONDON and BASKING RIDGE, N.J. , July 09, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a global commercial-stage
LONDON , and BASKING RIDGE, N.J. , June 24, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore TM , the company’s non-invasive vagus nerve stimulator (nVNS), will appear on the NHS Supply
BASKING RIDGE, N.J. , June 10, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frank R. Amato will be stepping down as Chief Executive Officer. Mr. Amato joined electroCore in 2012 and was named Chief Executive
